Testing Strategies to Improving Warfarin Adherence

This study has been completed.
Sponsor:
Collaborator:
Aetna, Inc.
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00622102
First received: January 15, 2008
Last updated: December 1, 2009
Last verified: December 2009
  Purpose

We are performing a research study to learn more about the control of an individual's blood thinning (anticoagulation) on warfarin. Individuals from an anticoagulation clinic are being asked to participate in order to see if a lottery which provides the opportunity to win money in combination with the use of the Med-eMonitor might be useful in helping patients to achieve better control of their anticoagulation therapy. Half of the participants will be enrolled in the lottery arm and the other half will be a control group who will receive the Med-eMonitor only.


Condition Intervention
Atrial Fibrillation
Deep Venous Thrombosis
Dilated Cardiomyopathies
Behavioral: Lottery arm (Lottery and Med-eMonitor)
Behavioral: Non-Lottery (Med-eMonitor only)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Health Services Research
Official Title: Testing Strategies to Improving Warfarin Adherence

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • anticoagulation control [ Time Frame: six months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • adherence [ Time Frame: six months ] [ Designated as safety issue: No ]

Enrollment: 101
Study Start Date: December 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
Behavioral: Lottery arm (Lottery and Med-eMonitor)
Lottery and Med-eMonitor
2
50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
Behavioral: Non-Lottery (Med-eMonitor only)
Med-eMonitor only

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 21 years old age or older
  • On warfarin managed at the AC clinic
  • Target INR 2.0-3.0 or 2.5-3.5
  • At maintenance phase of therapy (defined as stable INR with stable warfarin dosing over at least 2 consecutive visits)

Exclusion Criteria:

  • Do not have access to telephone line
  • Unwillingness to participate or to sign a consent form(refusal)
  • Inability to participate because of advances dementia, advanced Alzheimer's disease or other impairment affecting ability to provide informed consent and/or quality data or utilize the Med-eMonitor
  • Participation in a current study that does not permit participation in another study
  • End stage or terminal illness with anticipated life expectancy of 6 months or less
  • INR over the upper limit for the individual's range at the time of enrollment (e.g.,>3.0 or >3.5, depending on the target range)
  • Diagnosed with antiphospholipid antibody syndrome or abnormal INR prior to starting warfarin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00622102

Locations
United States, Pennsylvania
Hospital of the University of Pennsylvania Anticoagulation Management Center
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Aetna, Inc.
Investigators
Principal Investigator: Kevin G Volpp, M.D., Ph.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: Stephen E. Kimmel, M.D., M.S.C.E., University of Pennsylvania School of Medicine
ClinicalTrials.gov Identifier: NCT00622102     History of Changes
Other Study ID Numbers: 806634
Study First Received: January 15, 2008
Last Updated: December 1, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pennsylvania:
warfarin
adherence
Mechanical heart valves

Additional relevant MeSH terms:
Atrial Fibrillation
Cardiomyopathies
Cardiomyopathy, Dilated
Thrombosis
Venous Thromboembolism
Venous Thrombosis
Arrhythmias, Cardiac
Cardiomegaly
Cardiovascular Diseases
Embolism and Thrombosis
Heart Diseases
Pathologic Processes
Thromboembolism
Vascular Diseases
Warfarin
Anticoagulants
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 30, 2014